The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Rekhtina I.G.

Gematologicheskiĭ nauchnyĭ tsentr Ministerstva zdravookhraneniia Rossii

Mendeleeva L.P.

GNTs Minzdrava Rossii, Moskva

Stolyarevich E.S.

Moscow City Clinical Hospital Fifty-Two, Moscow Healthcare Department, Moscow, Russia

Gal'tseva I.V.

GNTs Minzdrava Rossii, Moskva

Povilaitite P.E.

Department of Experimental Pathology and Electron Microscopy, Rostov Regional Mortem Bureau, Rostov-on-Don, Russia

Biriukova L.S.

Gematologicheskiĭ nauchnyĭ tsentr Ministerstva zdravookhraneniia Rossii

Secondary monoclonal gammopathy after bone marrow autotransplantation as a cause of worse renal function in light chain immunoglobulin deposition disease

Authors:

Rekhtina I.G., Mendeleeva L.P., Stolyarevich E.S., Gal'tseva I.V., Povilaitite P.E., Biriukova L.S.

More about the authors

Journal: Therapeutic Archive. 2016;88(6): 80‑83

Read: 1504 times


To cite this article:

Rekhtina IG, Mendeleeva LP, Stolyarevich ES, Gal'tseva IV, Povilaitite PE, Biriukova LS. Secondary monoclonal gammopathy after bone marrow autotransplantation as a cause of worse renal function in light chain immunoglobulin deposition disease. Therapeutic Archive. 2016;88(6):80‑83. (In Russ.)
https://doi.org/10.17116/terarkh201688680-83

References:

  1. Nasr SH, Valeri AM, Cornell LD, Fidler ME, Sethi S, D'Agati VD, Leung N. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol. 2012;7(2):231-239
  2. Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand JP, Dispenzieri A, Song KW, Kyle RA; International Kidney and Monoclonal Gammopathy Research Group. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012;120(22):4292-4295.
  3. Bridoux F, Leung N, Hutchison CA, Touchard G, Sethi S, Fermand J-P, Picken MP, Herrera GA, Kastritis E, Merlini G, Roussel M, Fervenza FC, Dispenzieri A, Kyle RA, Nasr SH. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int. 2015;87:698-711.
  4. Fermand J-P, Bridoux F, Robert A, Kyle RA, Kastritis E, Weiss BM, Cook MA, Drayson MT, Dispenzieri A, Leung N. on behalf of the International Kidney and Monoclonal Gammopathy Research Group. How I treat monoclonal gammopathy of renal significance (MGRS). Blood. 2013;122:3583-3590.
  5. Bansal T, Hossain R, Mckane W, Snowden JA. Safety and efficacy of high dose melphalan and autologous stem cell transplantation prior to renal allograft in end-stage renal failure secondary to Monoclonal Immunoglobulin Deposition Disease. Cell Ther Transplant. 2011;10(3):1-4.
  6. Gertz MA. Managing light chain deposition disease. Leukemia Lymphoma. 2012;53(2):183-184.
  7. Leung N, Lager DJ, Gertz MA, Wilson K, Kanakiriya S, Fervenza FC. Long-term outcome of renal transplantation in light-chain deposition disease. Am J Kidney Dis. 2004;43:147-153.
  8. Weichman K, Dember LM, Prokaeva T, Wright DG, Quillen K, Rosenzweig M, Skinner M, Seldin DC, Sanchorawala V. Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant. 2006;38(5):339-343.
  9. Telio D, Shepherd J, Forrest D, Zypchen L, Barnett M, Nevill T, Song KW. High-dose melphalan followed by ASCT has favorable safety and effi cacy in selected patients with light chain deposition disease and light and heavy chain deposition disease. Bone Marrow Transplant. 2012;47(3):453-455.
  10. Lorenz EC, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman SR, Gastineau DA, Leung N. Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant. 2008;23:2052-2057.
  11. Royer B, Arnulf B, Martinez F, Roy L, Flageul B, Etienne I, Ronco P, Brouet JC, Fermand JP. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int. 2004;65(2):642-648.
  12. Harada K, Akai Y, Sakan H, Yamaguchi Y, Nakatani K, Iwano M, Saito Y. Resolution of mesangial light chain deposits 3 years after high-dose melphalan with autologous peripheral blood stem cell transplantation. Clin Nephrol. 2010;74(5):384-388.
  13. Rekhtina I, Golitsina E, Biriukova L. Nephropathy caused by non-amyloid organized and granular deposits as multiple myeloma syndrome. Terapevticheskii arkhiv. 2011;83(7):65-68. (In Russ.)
  14. Wadhera RK, Kyle RA, Larson DR, Dispenzieri A, Kumar S, Lazarus HM, Rajkumar SV. Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. Blood. 2011;118(11):2985-2987.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.